Maze Therapeutics Q4 EPS $(0.65) Beats $(0.71) Estimate

Benzinga Newsdesk www.benzinga.com Negative 96.9%

Neg 96.9% Neu 0% Pos 0%

Maze Therapeutics (NASDAQ:MAZE) reported quarterly losses of $(0.65) per share which beat the analyst consensus estimate of $(0.71) by 8.45 percent.